Macrogenics (MGNX) Cash from Restructuring (2012 - 2018)
Macrogenics (MGNX) posted quarterly Cash from Restructuring of -$298000.0 for Q1 2018, up 21.37% year-over-year from -$245526.1 in Q1 2017, and up 28.54% quarter-over-quarter from -$417000.0 in Q4 2017.
Powered by 
Analysis
Macrogenics (MGNX) Cash from Restructuring (2012 - 2018) Analysis & Trends
Macrogenics (MGNX) has reported Cash from Restructuring for 7 consecutive years, with -$298000.0 the latest figure, recorded in Q1 2018.
- In Q1 2018, Cash from Restructuring rose 21.37% year-over-year to -$298000.0; the TTM figure through Mar 2019 stood at -$298000.0 (up 80.29% YoY), while the FY2017 annual figure was -$1.6 million, up 43.55% from the prior year.
- Cash from Restructuring advanced to -$298000.0 in Q1 2018 per MGNX's latest filing, from -$417000.0 in the prior quarter.
- Across five years, Cash from Restructuring topped out at -$298000.0 in Q1 2018 and bottomed at -$2.0 million in Q2 2015.
- Historically, Cash from Restructuring has averaged -$555588.2 across 5 years, with a median of -$392000.0 in 2017.
- Annual changes were most pronounced in 2015 — Cash from Restructuring plunged 459.72% — and 2017, when it soared 76.18%.
- Macrogenics' Cash from Restructuring stood at -$372000.0 in 2014, then retreated by 23.66% to -$460000.0 in 2015, then increased by 24.13% to -$349000.0 in 2016, then slipped by 19.48% to -$417000.0 in 2017, then rose by 28.54% to -$298000.0 in 2018.
- Business Quant data shows MGNX's Cash from Restructuring at -$298000.0 in Q1 2018, -$417000.0 in Q4 2017, and -$405000.0 in Q3 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2018 | -298,000.00 |
| Dec 31, 2017 | -417,000.00 |
| Sep 30, 2017 | -405,000.00 |
| Jun 30, 2017 | -392,000.00 |
| Mar 31, 2017 | -379,000.00 |
| Dec 31, 2016 | -349,000.00 |
| Sep 30, 2016 | -339,000.00 |
| Jun 30, 2016 | -1.65 Mn |
| Mar 31, 2016 | -488,000.00 |
| Dec 31, 2015 | -460,000.00 |
| Sep 30, 2015 | -450,000.00 |
| Jun 30, 2015 | -1.99 Mn |
| Mar 31, 2015 | -396,000.00 |
| Dec 31, 2014 | -372,000.00 |
| Sep 30, 2014 | -364,000.00 |
| Jun 30, 2014 | -355,000.00 |
| Mar 31, 2014 | -348,000.00 |
| Dec 31, 2013 | -163,000.00 |
| Sep 30, 2013 | -159,000.00 |
| Jun 30, 2013 | -155,005.00 |